B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies

Outcomes of patients with multiple myeloma (MM) who become refractory to standard therapies are particularly poor and novel agents are greatly needed to improve outcomes in such patients. B-cell maturation antigen (BCMA) has become an important therapeutic target in MM with three modalities of treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez, Larysa, Dardac, Alexandra, Madduri, Deepu, Richard, Shambavi, Richter, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Advances in Multiple Myeloma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970693/
https://www.ncbi.nlm.nih.gov/pubmed/33796236
http://dx.doi.org/10.1177/2040620721989585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970693/
https://www.ncbi.nlm.nih.gov/pubmed/33796236
http://dx.doi.org/10.1177/2040620721989585

Ejemplares similares